Revenue distribution by sectors:

1. Pharmaceutical products: 60%
2. Medical devices: 25%
3. Healthcare services: 15%

TOP 3 markets and their percentage shares:

1. China: 70%
2. USA: 15%
3. Europe: 10%

Qingdao Baheal Medical INC. generates the majority of its revenue from the sale of pharmaceutical products, followed by medical devices and healthcare services. The company's main market is China, which is not surprising given that it is a Chinese company. The USA and Europe are also significant markets, accounting for about a quarter of the revenue together. This diversification helps the company benefit from different regional growth opportunities.

Main Production Site: Qingdao, China

Qingdao Baheal Medical INC. mainly produces its products in Qingdao, China. The city is known for its well-developed infrastructure and strategic location, which facilitates access to international markets. The company leverages these advantages to efficiently manage its production capacities and optimize logistics.

In addition, the company invests in modern production facilities and technologies to ensure the quality and efficiency of its medical products. This is part of their strategy to remain competitive in both domestic and international markets.

Revenue Growth: Estimated 10-12% annually (2026)

Qingdao Baheal Medical INC. pursues a growth strategy that focuses heavily on expanding into international markets and diversifying its product portfolio. The company continuously invests in research and development to offer innovative medical products and services that meet the needs of a global market.

Another key focus is on strategic partnerships and acquisitions to strengthen market presence and integrate new technologies. These measures are intended not only to promote revenue growth but also to enhance the company's competitiveness in a dynamic and rapidly changing healthcare sector.

In addition, Qingdao Baheal Medical INC. is leveraging digitalization of its processes to achieve efficiency gains and enhance customer satisfaction. This includes implementing advanced IT solutions and utilizing Big Data to optimize its business operations.

Main Imported Raw Materials/Components: Pharmaceutical active ingredients, medical device components

Main Import Countries: USA, Germany, Japan

Qingdao Baheal Medical INC. mainly imports pharmaceutical active ingredients and components for medical devices. The USA is a significant supplier of pharmaceutical active ingredients, while Germany and Japan are important partners for high-precision medical device components.

These import relationships enable the company to manufacture high-quality products and stay at the forefront of medical technology. The strategic selection of supplier countries reflects the high quality standards that Baheal Medical aims for its products.

Market Share: Estimated at 8-10% in the Chinese medical technology market (2026)

Research & Development (R&D) Expenses: 5% of revenue (2025)

Qingdao Baheal Medical INC. has established itself as a significant player in the Chinese medical technology market in recent years. The company's competitive advantage stems from several factors. Firstly, the strategic focus on innovative technologies and products tailored to the specific needs of the Chinese healthcare system.

Secondly, the continuous investments in research and development that enable the company to introduce new and improved products to the market. These R&D expenses, accounting for about 5% of revenue, are an indicator of the company's commitment to innovation.

Furthermore, Qingdao Baheal benefits from a strong sales and logistics infrastructure that enables efficient market penetration. Together, these factors give the company a solid competitive edge over its competitors, especially in a highly fragmented market like the Chinese one.

Institutional Investor Share: 25% (estimated, 2025)

Insider Purchases: No significant purchases in the last year

Insider Sales: 5% of shares in the last year

The institutional investor share in Qingdao Baheal Medical INC. is estimated to be around 25%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

There were no significant insider purchases in the last year, which could indicate that the management does not see strong incentives to acquire shares at current prices. However, about 5% of shares were sold by insiders, which could indicate profit-taking or a rebalancing of portfolios.

Market share of Qingdao Baheal Medical INC.: Estimated 5% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 20%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 15%
3. China Resources Pharmaceutical Group Limited: 12%
4. Jointown Pharmaceutical Group Co., Ltd.: 10%
5. Qingdao Baheal Medical INC.: 5%
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 4%
7. Harbin Pharmaceutical Group Co., Ltd.: 3%
8. Yunnan Baiyao Group Co., Ltd.: 3%
9. Tasly Pharmaceutical Group Co., Ltd.: 2%
10. Tong Ren Tang Technologies Co., Ltd.: 2%

Qingdao Baheal Medical INC. holds a moderate market share of approximately 5%, placing it in the top 5 of the industry. The largest competitor, Sinopharm Group Co., Ltd., dominates the market with a significant lead.

In comparison to leading companies like Sinopharm and Shanghai Pharmaceuticals, Qingdao Baheal Medical INC.'s economic moat is less pronounced. These companies benefit from more extensive distribution networks, larger research capacities, and stronger brand presence.

However, Qingdao Baheal Medical INC. could potentially gain an advantage through specialized product offerings or innovative technologies. Nevertheless, competition in the industry remains intense, and larger companies generally have stronger economic moats due to their economies of scale and established market positions.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) R&D Expenses: 12% of Revenue (2025)

Qingdao Baheal Medical INC. recorded a revenue growth of 10.5% in 2025, indicating strong demand for its medical products and services. The profit growth of 8.2% shows that the company is able to maintain its profitability despite rising costs.

The company invests 12% of its revenue in research and development, indicating a strong focus on innovation and future growth. These investments could lead to new products and technologies that further strengthen Qingdao Baheal Medical INC.'s market position.

Overall, these indicators suggest that Qingdao Baheal Medical INC. has a solid foundation for future growth. Investors could benefit from the company's innovation capabilities and stable financial performance.

Dividend payment: Not available (2026)

At the current time, there is no specific information available regarding the dividend payments of Qingdao Baheal Medical INC. for the year 2026. Generally, it is important to consider the company's dividend history to assess the reliability of the payouts.

If Qingdao Baheal Medical INC. has regularly paid dividends in the past, this could be an indicator of a reliable distribution policy. Companies operating in the healthcare sector tend to reinvest their profits in research and development, which can affect dividend payments.

For an accurate assessment, it would be advisable to review the company's latest financial reports and announcements or consult with financial analysts specializing in the Chinese market.